FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133584248> ?p ?o ?g. }

• W3133584248 endingPage "104" @default.
• W3133584248 startingPage "95" @default.
• W3133584248 abstract "Inflammation is associated with end-organ disease and mortality for people with human immunodeficiency virus (PWH). Ruxolitinib, a Jak 1/2 inhibitor, reduces systemic inflammation for individuals without human immunodeficiency virus (HIV) and HIV reservoir markers ex vivo. The goal of this trial was to determine safety and efficacy of ruxolitinib for PWH on antiretroviral therapy (ART).AIDS Clinical Trials Group (ACTG) A5336 was an open-label, multisite, randomized controlled trial (RCT). Participants were randomly assigned (2:1) using centralized software to ruxolitinib (10 mg twice daily) plus stable ART for 5 weeks vs ART alone, stratified by efavirenz use. Eligible participants were suppressed on ART for ≥2 years, without comorbidities, and had >350 CD4+ T cells/µL. Primary endpoints were premature discontinuation, safety events, and change in plasma interleukin 6 (IL-6). Secondary endpoints included other measures of inflammation/immune activation and HIV reservoir.Sixty participants were enrolled from 16 May 2016 to 10 January 2018. Primary safety events occurred in 2.5% (1 participant) for ruxolitinib and 0% for controls (P = .67). Three participants (7.5%) prematurely discontinued ruxolitinib. By week 5, differences in IL-6 (mean fold change [FC], 0.93 vs 1.10; P = .18) and soluble CD14 (mean FC, 0.96 vs 1.08; relative FC, 0.96 [90% confidence interval {CI}, .90-1.02]) levels for ruxolitinib vs controls was observed. Ruxolitinib reduced CD4+ T cells expressing HLA-DR/CD38 (mean difference, -0.34% [90% CI, -.66% to -.12%]) and Bcl-2 (mean difference, -3.30% [90% CI, -4.72% to -1.87%]).In this RCT of healthy, virologically suppressed PWH on ART, ruxolitinib was well-tolerated. Baseline IL-6 levels were normal and showed no significant reduction. Ruxolitinib significantly decreased markers of immune activation and cell survival. Future studies of Jak inhibitors should target PWH with residual inflammation despite suppressive ART.NCT02475655." @default.
• W3133584248 created "2021-03-15" @default.
• W3133584248 creator A5013698403 @default.
• W3133584248 creator A5013736817 @default.
• W3133584248 creator A5017420608 @default.
• W3133584248 creator A5027304381 @default.
• W3133584248 creator A5035584213 @default.
• W3133584248 creator A5039616877 @default.
• W3133584248 creator A5040099496 @default.
• W3133584248 creator A5040869308 @default.
• W3133584248 creator A5053117575 @default.
• W3133584248 creator A5053867160 @default.
• W3133584248 creator A5058155385 @default.
• W3133584248 creator A5063704053 @default.
• W3133584248 creator A5065731602 @default.
• W3133584248 creator A5072899489 @default.
• W3133584248 creator A5072982903 @default.
• W3133584248 creator A5073223457 @default.
• W3133584248 creator A5075575064 @default.
• W3133584248 creator A5087052821 @default.
• W3133584248 creator A5087476756 @default.
• W3133584248 date "2021-03-06" @default.
• W3133584248 modified "2023-10-15" @default.
• W3133584248 title "Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus" @default.
• W3133584248 cites W151256503 @default.
• W3133584248 cites W2004471105 @default.
• W3133584248 cites W2007130444 @default.
• W3133584248 cites W2012249056 @default.
• W3133584248 cites W2031251938 @default.
• W3133584248 cites W2034952572 @default.
• W3133584248 cites W2038197512 @default.
• W3133584248 cites W2046166857 @default.
• W3133584248 cites W2046351301 @default.
• W3133584248 cites W2047542844 @default.
• W3133584248 cites W2056954848 @default.
• W3133584248 cites W2059317991 @default.
• W3133584248 cites W2095498566 @default.
• W3133584248 cites W2098836196 @default.
• W3133584248 cites W2124114936 @default.
• W3133584248 cites W2140573695 @default.
• W3133584248 cites W2150050151 @default.
• W3133584248 cites W2159360702 @default.
• W3133584248 cites W2269475025 @default.
• W3133584248 cites W2322243210 @default.
• W3133584248 cites W2418937816 @default.
• W3133584248 cites W2589237569 @default.
• W3133584248 cites W2603282311 @default.
• W3133584248 cites W2777514158 @default.
• W3133584248 cites W2914209107 @default.
• W3133584248 cites W2953142604 @default.
• W3133584248 cites W2954026473 @default.
• W3133584248 cites W2970831199 @default.
• W3133584248 cites W3008526620 @default.
• W3133584248 cites W3016114557 @default.
• W3133584248 cites W3113196149 @default.
• W3133584248 doi "https://doi.org/10.1093/cid/ciab212" @default.
• W3133584248 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33693561" @default.
• W3133584248 hasPublicationYear "2021" @default.
• W3133584248 type Work @default.
• W3133584248 sameAs 3133584248 @default.
• W3133584248 citedByCount "27" @default.
• W3133584248 countsByYear W31335842482021 @default.
• W3133584248 countsByYear W31335842482022 @default.
• W3133584248 countsByYear W31335842482023 @default.
• W3133584248 crossrefType "journal-article" @default.
• W3133584248 hasAuthorship W3133584248A5013698403 @default.
• W3133584248 hasAuthorship W3133584248A5013736817 @default.
• W3133584248 hasAuthorship W3133584248A5017420608 @default.
• W3133584248 hasAuthorship W3133584248A5027304381 @default.
• W3133584248 hasAuthorship W3133584248A5035584213 @default.
• W3133584248 hasAuthorship W3133584248A5039616877 @default.
• W3133584248 hasAuthorship W3133584248A5040099496 @default.
• W3133584248 hasAuthorship W3133584248A5040869308 @default.
• W3133584248 hasAuthorship W3133584248A5053117575 @default.
• W3133584248 hasAuthorship W3133584248A5053867160 @default.
• W3133584248 hasAuthorship W3133584248A5058155385 @default.
• W3133584248 hasAuthorship W3133584248A5063704053 @default.
• W3133584248 hasAuthorship W3133584248A5065731602 @default.
• W3133584248 hasAuthorship W3133584248A5072899489 @default.
• W3133584248 hasAuthorship W3133584248A5072982903 @default.
• W3133584248 hasAuthorship W3133584248A5073223457 @default.
• W3133584248 hasAuthorship W3133584248A5075575064 @default.
• W3133584248 hasAuthorship W3133584248A5087052821 @default.
• W3133584248 hasAuthorship W3133584248A5087476756 @default.
• W3133584248 hasBestOaLocation W31335842481 @default.
• W3133584248 hasConcept C126322002 @default.
• W3133584248 hasConcept C142462285 @default.
• W3133584248 hasConcept C168563851 @default.
• W3133584248 hasConcept C203014093 @default.
• W3133584248 hasConcept C203092338 @default.
• W3133584248 hasConcept C2776112149 @default.
• W3133584248 hasConcept C2778715236 @default.
• W3133584248 hasConcept C2780007613 @default.
• W3133584248 hasConcept C2780076729 @default.
• W3133584248 hasConcept C2781432083 @default.
• W3133584248 hasConcept C2993143319 @default.
• W3133584248 hasConcept C3013748606 @default.
• W3133584248 hasConcept C71924100 @default.

• next